Latest News & Features
Big Pharma
UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies. 13 April 2021
Americas
Brazil’s highest court has suspended extensions of drug patents due to the public health emergency caused by COVID-19. 8 April 2021
article
Without patent protection, efforts to commercialise a repurposed drug have little chance for a reasonable return and are unlikely to attract outside investment. Repurposing drugs can be extremely fruitful for companies as long as proper patent protection is in place. There are a few barriers to consider when trying to patent protect repurposed drugs. 8 April 2021
Big Pharma
The UK government’s £20 million fund aimed at growing life sciences manufacturing is now open for applications, it confirmed today, April 7. 8 April 2021
Medtech
Honeywell has been targeted in a recent complaint from competitor Moldex-Metric over a newly-launched “antimicrobial” earplug dispenser, which Moldex claims is falsely advertised. 6 April 2021
Americas
Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission. 6 April 2021
Medtech
Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi 1 April 2021
Americas
The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office. 1 April 2021
Medtech
In a win for medical device maker Arthrex, a federal judge in Delaware has ruled that its wrist-plating system does not infringe a patent owned by competitor TriMed Technologies. 30 March 2021
Europe
Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics. 30 March 2021